{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T23:14:37Z","timestamp":1789168477672,"version":"build-2803163510"},"reference-count":62,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Microbe"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.lanmic.2026.101413","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T13:54:03Z","timestamp":1778766843000},"page":"101413","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Treatment strategies for imipenemase-producing Gram-negative infections: lessons from Japan"],"prefix":"10.1016","volume":"7","author":[{"given":"Daisuke","family":"Ono","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sohei","family":"Harada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshikazu","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria F","family":"Mojica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A","family":"Bonomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lanmic.2026.101413_bib1","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1016\/S1473-3099(20)30868-9","article-title":"The urgent need for metallo-\u03b2-lactamase inhibitors: an unattended global threat","volume":"22","author":"Mojica","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.lanmic.2026.101413_bib2","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01076-18","article-title":"Past and present perspectives on \u03b2-lactamases","volume":"62","author":"Bush","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.lanmic.2026.101413_bib3","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.2174\/1389450116666151001105622","article-title":"B1-metallo-\u03b2-lactamases: where do we stand?","volume":"17","author":"Mojica","year":"2016","journal-title":"Curr Drug Targets"},{"key":"10.1016\/j.lanmic.2026.101413_bib4","first-page":"3523","article-title":"Evaluation of the NG-Test CARBA 5 multiplex immunochromatographic assay for the detection of KPC, OXA-48-like, NDM, VIM and IMP carbapenemases","volume":"73","author":"Hopkins","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.lanmic.2026.101413_bib5","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1080\/14756366.2017.1344235","article-title":"Beta-lactamase database (BLDB) - structure and function","volume":"32","author":"Naas","year":"2017","journal-title":"J Enzyme Inhib Med Chem"},{"key":"10.1016\/j.lanmic.2026.101413_bib6","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1128\/AAC.35.1.147","article-title":"Transferable imipenem resistance in Pseudomonas aeruginosa","volume":"35","author":"Watanabe","year":"1991","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.lanmic.2026.101413_bib7","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1128\/AAC.38.1.71","article-title":"Molecular characterization of an enterobacterial metallo beta-lactamase found in a clinical isolate of Serratia marcescens that shows imipenem resistance","volume":"38","author":"Osano","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.lanmic.2026.101413_bib8","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02729-16","article-title":"Global molecular epidemiology of IMP-producing Enterobacteriaceae","volume":"61","author":"Matsumura","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.lanmic.2026.101413_bib9","doi-asserted-by":"crossref","first-page":"236","DOI":"10.3390\/antibiotics11020236","article-title":"Comprehensive analysis of imipenemase (IMP)-type metallo-\u03b2-lactamase: a global distribution threatening Asia","volume":"11","author":"Pongchaikul","year":"2022","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.lanmic.2026.101413_bib11","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jgar.2024.05.009","article-title":"In vitro activity of cefiderocol against carbapenemase-producing and meropenem-non-susceptible Gram-negative bacteria collected in the Japan Antimicrobial Resistant Bacterial Surveillance","volume":"38","author":"Kayama","year":"2024","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.lanmic.2026.101413_bib12","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/QCO.0000000000000182","article-title":"The role of surveillance systems in confronting the global crisis of antibiotic-resistant bacteria","volume":"28","author":"Perez","year":"2015","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.lanmic.2026.101413_bib13","doi-asserted-by":"crossref","first-page":"7957","DOI":"10.1021\/acs.chemrev.1c00138","article-title":"Metallo-\u03b2-lactamases in the age of multidrug resistance: from structure and mechanism to evolution, dissemination, and inhibitor design","volume":"121","author":"Bahr","year":"2021","journal-title":"Chem Rev"},{"key":"10.1016\/j.lanmic.2026.101413_bib37","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00687-24","article-title":"The interaction of the azetidine thiazole side chain with the active site loop (ASL) 3 drives the evolution of IMP metallo-\u03b2-lactamase against tebipenem","volume":"68","author":"Ono","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.lanmic.2026.101413_bib38","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1021\/acsinfecdis.2c00395","article-title":"Difference in the inhibitory effect of thiol compounds and demetallation rates from the Zn(II) active site of metallo-\u03b2-lactamases (IMP-1 and IMP-6) associated with a single amino acid substitution","volume":"9","author":"Yamaguchi","year":"2023","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.lanmic.2026.101413_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2022.101665","article-title":"Deciphering the evolution of metallo-\u03b2-lactamases: a journey from the test tube to the bacterial periplasm","volume":"298","author":"L\u00f3pez","year":"2022","journal-title":"J Biol Chem"},{"key":"10.1016\/j.lanmic.2026.101413_bib40","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1002\/pro.2530","article-title":"Understanding the determinants of substrate specificity in IMP family metallo-\u03b2-lactamases: the importance of residue 262","volume":"23","author":"Pegg","year":"2014","journal-title":"Protein Sci"},{"key":"10.1016\/j.lanmic.2026.101413_bib41","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01168-23","article-title":"Structural basis of metallo-\u03b2-lactamase resistance to taniborbactam","volume":"68","author":"Drusin","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.lanmic.2026.101413_bib42","doi-asserted-by":"crossref","first-page":"7299","DOI":"10.1128\/AAC.01651-15","article-title":"Elucidating the role of residue 67 in IMP-type metallo-\u03b2-lactamase evolution","volume":"59","author":"LaCuran","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.lanmic.2026.101413_bib43","doi-asserted-by":"crossref","first-page":"6403","DOI":"10.1128\/AAC.01440-12","article-title":"The sequence-activity relationship between metallo-\u03b2-lactamases IMP-1, IMP-6, and IMP-25 suggests an evolutionary adaptation to meropenem exposure","volume":"56","author":"Liu","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.lanmic.2026.101413_bib44","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01714-20","article-title":"Carbapenem use is driving the evolution of imipenemase 1 variants","volume":"65","author":"Cheng","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.lanmic.2026.101413_bib45","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1093\/jb\/mvac080","article-title":"Structural insights into the substrate specificity of IMP-6 and IMP-1 metallo-\u03b2-lactamases","volume":"173","author":"Yamamoto","year":"2022","journal-title":"J Biochem"},{"key":"10.1016\/j.lanmic.2026.101413_bib46","doi-asserted-by":"crossref","first-page":"8945","DOI":"10.1021\/bi0300332","article-title":"Modeling domino effects in enzymes: molecular basis of the substrate specificity of the bacterial metallo-beta-lactamases IMP-1 and IMP-6","volume":"42","author":"Oelschlaeger","year":"2003","journal-title":"Biochemistry"},{"key":"10.1016\/j.lanmic.2026.101413_bib47","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1110\/ps.041093405","article-title":"Impact of remote mutations on metallo-beta-lactamase substrate specificity: implications for the evolution of antibiotic resistance","volume":"14","author":"Oelschlaeger","year":"2005","journal-title":"Protein Sci"},{"key":"10.1016\/j.lanmic.2026.101413_bib48","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.jmb.2006.11.027","article-title":"Hydroxyl groups in the \u03b2\u03b2 sandwich of metallo-\u03b2-lactamases favor enzyme activity: Tyr218 and Ser262 pull down the lid","volume":"366","author":"Oelschlaeger","year":"2007","journal-title":"J Mol Biol"},{"key":"10.1016\/j.lanmic.2026.101413_bib49","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1128\/JCM.02649-12","article-title":"Meropenem resistance in imipenem-susceptible meropenem-resistant Klebsiella pneumoniae isolates not detected by rapid automated testing systems","volume":"51","author":"Harino","year":"2013","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.lanmic.2026.101413_bib50","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S1473-3099(23)00069-5","article-title":"NDM-9 resistance to taniborbactam","volume":"23","author":"Le Terrier","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.lanmic.2026.101413_bib51","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00991-23","article-title":"Relative inhibitory activities of the broad-spectrum \u03b2-lactamase inhibitor xeruborbactam in comparison with taniborbactam against metallo-\u03b2-lactamases produced in Escherichia coli and Pseudomonas aeruginosa","volume":"68","author":"Le Terrier","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.lanmic.2026.101413_bib52","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01432-20","article-title":"In vitro activity of WCK 5222 (cefepime-zidebactam) against worldwide collected Gram-negative bacilli not susceptible to carbapenems","volume":"64","author":"Karlowsky","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.lanmic.2026.101413_bib53","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1093\/jac\/dky522","article-title":"Activity of nacubactam (RG6080\/OP0595) combinations against MBL-producing Enterobacteriaceae","volume":"74","author":"Mushtaq","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.lanmic.2026.101413_bib54","article-title":"In vitro and in vivo activities of KSP-1007, a broad-spectrum inhibitor of serine- and metallo-\u03b2-lactamases, in combination with meropenem against carbapenem-resistant Gram-negative bacteria","volume":"68","author":"Takemoto","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.lanmic.2026.101413_bib55","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciae403","article-title":"Infectious Diseases Society of America 2024 guidance on the treatment of antimicrobial-resistant Gram-negative infections","author":"Tamma","year":"2024","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.lanmic.2026.101413_bib56","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1093\/jac\/dkaa197","article-title":"Determining the optimal dosing of a novel combination regimen of ceftazidime\/avibactam with aztreonam against NDM-1-producing Enterobacteriaceae using a hollow-fibre infection model","volume":"75","author":"Lodise","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.lanmic.2026.101413_bib57","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1093\/jac\/dkaa549","article-title":"Pragmatic options for dose optimization of ceftazidime\/avibactam with aztreonam in complex patients","volume":"76","author":"Falcone","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.lanmic.2026.101413_bib58","article-title":"Pharmacokinetics of ceftazidime-avibactam in combination with aztreonam (COMBINE) in a phase 1, open-label study of healthy adults","volume":"66","author":"Lodise","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.lanmic.2026.101413_bib27","article-title":"Activity of aztreonam-avibactam, cefiderocol, and cefepime-taniborbactam against a global collection of genetically characterized metallo-\u03b2-lactamase-producing Enterobacterales","volume":"70","author":"Castanheira","year":"2025","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.lanmic.2026.101413_bib60","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/S1473-3099(24)00499-7","article-title":"Aztreonam\u2013avibactam versus meropenem for the treatment of serious infections caused by Gram-negative bacteria (REVISIT): a descriptive, multinational, open-label, phase 3, randomised trial","volume":"25","author":"Carmeli","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.lanmic.2026.101413_bib61","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1093\/jac\/dkaa021","article-title":"High prevalence of Escherichia coli clinical isolates in India harbouring four-amino-acid inserts in PBP3 adversely impacting activity of aztreonam\/avibactam","volume":"75","author":"Periasamy","year":"2020","journal-title":"J Antimicrob Chemother"},{"issue":"suppl 7","key":"10.1016\/j.lanmic.2026.101413_bib62","doi-asserted-by":"crossref","first-page":"S538","DOI":"10.1093\/cid\/ciz826","article-title":"Cefiderocol: discovery, chemistry, and in vivo profiles of a novel siderophore cephalosporin","volume":"69","author":"Sato","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.lanmic.2026.101413_bib63","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1089\/mdr.2022.0279","article-title":"In vitro activity of cefiderocol against meropenem-nonsusceptible Gram-negative bacilli with defined \u03b2-lactamase carriage: SIDERO-WT surveillance studies, 2014\u20132019","volume":"29","author":"Wise","year":"2023","journal-title":"Microb Drug Resist"},{"key":"10.1016\/j.lanmic.2026.101413_bib28","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S1473-3099(20)30796-9","article-title":"Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial","volume":"21","author":"Bassetti","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.lanmic.2026.101413_bib29","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.3390\/antibiotics10081012","article-title":"The revival of aztreonam in combination with avibactam against metallo-\u03b2-lactamase-producing Gram-negatives: a systematic review of in vitro studies and clinical cases","volume":"10","author":"Mauri","year":"2021","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.lanmic.2026.101413_bib30","first-page":"36","article-title":"Antimicrobial resistance profiles in multidrug-resistant Pseudomonas aeruginosa isolates in a university hospital in Argentina. Activity of new antibiotic combinations","volume":"58","author":"Alvarez","year":"2026","journal-title":"Rev Argent Microbiol"},{"key":"10.1016\/j.lanmic.2026.101413_bib31","article-title":"Comparison of in vitro activity of ceftazidime-avibactam and imipenem-relebactam against clinical isolates of Pseudomonas aeruginosa","volume":"11","author":"Wang","year":"2023","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.lanmic.2026.101413_bib32","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.02079-25","volume":"13","author":"Kimbrough","year":"2025","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.lanmic.2026.101413_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2025.107550","article-title":"In vitro activity of cefepime-zidebactam, ceftolozane-tazobactam, ceftazidime-avibactam, imipenem-relebactam, and other comparators against imipenem-non-susceptible Pseudomonas aeruginosa in Taiwan, 2022","volume":"66","author":"Lee","year":"2025","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.lanmic.2026.101413_bib34","doi-asserted-by":"crossref","DOI":"10.1093\/jacamr\/dlae135","article-title":"Prevalence of carbapenem-resistant Enterobacterales with blaIMP-6 predominance in hospitals from 2018 to 2021 in Nara, Japan","volume":"6","author":"Kishi","year":"2024","journal-title":"JAC Antimicrob Resist"},{"key":"10.1016\/j.lanmic.2026.101413_bib14","doi-asserted-by":"crossref","first-page":"8046","DOI":"10.1038\/s41467-023-43516-4","article-title":"National genomic surveillance integrating standardized quantitative susceptibility testing clarifies antimicrobial resistance in Enterobacterales","volume":"14","author":"Kayama","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.lanmic.2026.101413_bib35","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.jgar.2024.06.020","article-title":"Transmission of global clones of NDM-producing Enterobacterales and interspecies spread of IncX3 plasmid harbouring blaNDM-5 in Tokyo","volume":"38","author":"Harada","year":"2024","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.lanmic.2026.101413_bib36","article-title":"The role of trimethoprim\/sulfamethoxazole in the treatment of infections caused by carbapenem-resistant Enterobacteriaceae","volume":"6","author":"Luterbach","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.lanmic.2026.101413_bib64","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1001\/jama.2015.12480","article-title":"Epidemiology of carbapenem-resistant Enterobacteriaceae in 7 US communities, 2012-2013","volume":"314","author":"Guh","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.lanmic.2026.101413_bib65","doi-asserted-by":"crossref","first-page":"314","DOI":"10.3389\/fcimb.2020.00314","article-title":"Dissemination of carbapenemases (KPC, NDM, OXA-48, IMP, and VIM) among carbapenem-resistant Enterobacteriaceae isolated from adult and children patients in China","volume":"10","author":"Han","year":"2020","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.lanmic.2026.101413_bib18","doi-asserted-by":"crossref","first-page":"2984","DOI":"10.1128\/AAC.01634-07","article-title":"blaIMP-4 in different genetic contexts in Enterobacteriaceae isolates from Australia","volume":"52","author":"Espedido","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.lanmic.2026.101413_bib19","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1086\/497831","article-title":"Dissemination of the metallo-\u03b2-lactamase gene blaIMP-4 among Gram-negative pathogens in a clinical setting in Australia","volume":"41","author":"Peleg","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.lanmic.2026.101413_bib20","article-title":"Molecular characterization of blaIMP-4-carrying Enterobacterales in Henan Province of China","volume":"12","author":"Liu","year":"2021","journal-title":"Front Microbiol"},{"key":"10.1016\/j.lanmic.2026.101413_bib21","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s12941-023-00588-w","article-title":"Molecular characteristics of clinical IMP-producing Klebsiella pneumoniae isolates: novel IMP-90 and integron In2147","volume":"22","author":"Yang","year":"2023","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"10.1016\/j.lanmic.2026.101413_bib22","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.00107-24","article-title":"Effect of ceftazidime-avibactam combined with different antimicrobials against carbapenem-resistant Klebsiella pneumoniae","volume":"12","author":"Wu","year":"2024","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.lanmic.2026.101413_bib15","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01672-23","article-title":"Clinical and genomic characteristics of IMP-producing Enterobacter cloacae complex and Klebsiella pneumoniae","volume":"68","author":"Suzuki","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.lanmic.2026.101413_bib17","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1186\/s12879-021-05952-9","article-title":"Institutional outbreak involving multiple clades of IMP-producing Enterobacter cloacae complex sequence type 78 at a cancer center in Tokyo, Japan","volume":"21","author":"Harada","year":"2021","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.lanmic.2026.101413_bib24","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.jiac.2018.11.012","article-title":"Molecular and epidemiological analysis of IMP-1 metallo-\u03b2-lactamase-producing Klebsiella pneumoniae in a tertiary care hospital in Japan","volume":"25","author":"Yamakawa","year":"2019","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.lanmic.2026.101413_bib25","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1093\/jac\/dkz501","article-title":"Comparison between IMP carbapenemase-producing Enterobacteriaceae and non-carbapenemase-producing Enterobacteriaceae: a multicentre prospective study of the clinical and molecular epidemiology of carbapenem-resistant Enterobacteriaceae","volume":"75","author":"Hayakawa","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.lanmic.2026.101413_bib26","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.jgar.2022.04.004","article-title":"Clinical characteristics and treatment outcomes of carbapenem-resistant Enterobacterales infections in Japan","volume":"29","author":"Oka","year":"2022","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.lanmic.2026.101413_bib16","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01483-20","article-title":"A matched case-case-control study of the impact of clinical outcomes and risk factors of patients with IMP-type carbapenemase-producing carbapenem-resistant Enterobacteriaceae in Japan","volume":"65","author":"Saito","year":"2021","journal-title":"Antimicrob Agents Chemother"}],"container-title":["The Lancet Microbe"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666524726000686?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666524726000686?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T22:49:39Z","timestamp":1789166979000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666524726000686"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":62,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2666524726000686"],"URL":"https:\/\/doi.org\/10.1016\/j.lanmic.2026.101413","relation":{},"ISSN":["2666-5247"],"issn-type":[{"value":"2666-5247","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment strategies for imipenemase-producing Gram-negative infections: lessons from Japan","name":"articletitle","label":"Article Title"},{"value":"The Lancet Microbe","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lanmic.2026.101413","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101413"}}